RS Research

Seasons have their own kind of energy. Not because they change who we are; but because they bring a new rhythm to our work; more motivation to our team's smiles.

There is something about this time of year that sharpens the pace. March has carried us through long days, more miles and the kind of momentum that reminds us how alive this ecosystem really is.

As a clinical-stage team advancing Sagitta®, we feel that energy as fuel that pushes us to keep asking better questions and keep moving strong science toward wider impact. If March is any sign, the months ahead will ask even more of all of us. And we are ready for that tempo, with excitement for what it can bring. 🌺



w/ Sena Nomak | Rana Sanyal

It feels like Paris will hold the heartbeat of what comes next for next-generation therapies next week.

European Deeptech Week by Bpifrance and EuroQuitywith its special focus on Europe’s most promising start-ups such as RS Research, will dive into many critical questions. One is about how promising science earns its place in clinical practice. Another is about how deeptech earns scale and relevance in the real world.

At RS Research, this is a strong reflection of how we advance our technology toward excellence. Targeted delivery only becomes meaningful when strong science, disciplined development and business readiness move in the same direction.

Join our Co-founder and COO, Dr. Sena Nomak, at the European 2026 hin Paris from 16 March to 20 March and let’s discover what comes next.

Accuracy is more than a metric: it’s a mindset. At RS Research, we approach every formulation, every molecule, every trial with relentless focus. Our science demands it: because when lives are at stake, there’s no room for “almost.”

With accurate targeting and rigorous testing, we create therapies that go precisely where they're needed. It’s how we redefine reliability in modern drug delivery.

Our peRSpective: accuracy is the science behind every smile.



*“ ” reflects RS Research’s way of defining a series of key concepts, and our success stems from this difference in perception.